Navigation Links
ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Date:1/5/2012

osis, both the mutant and normal forms of TTR can build up as fibrils in tissues, including heart, peripheral nerves, and the gastrointestinal tract.  The presence of TTR aggregates interferes with the normal functions of these tissues, and as the TTR protein aggregates enlarge more tissue damage occurs and the disease worsens.  There are two common types of transthyretin amyloidosis, familial amyloid cardiomyopathy, or FAC, which affects more than 40,000 patients worldwide, and FAP, which affects more than 10,000 patients worldwide.  Patients with FAC have TTR build up in the heart muscle and succumb to heart failure five to six years after symptom onset.  Patients with FAP have TTR build up in peripheral nerve tissue leading to the loss of nerve function and wasting.  ISIS-TTRRx is an investigational drug that is designed to inhibit the production of all forms of TTR, and could offer an alternative approach to treat all types of transthyretin-related amyloidosis. 

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis' collaboration with GlaxoSmithKline, the discovery, development and potential of drugs for severe and rare diseas
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
2. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
3. Cardium Reports on Renewed Compliance With NYSE Amex Exchange Listing Guidelines
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Solos Endoscopy, Inc. Reports Significant Sales From Its MammoView® Instrument Line
6. VIVUS Reports Topline Findings From FORTRESS
7. Angeion Corporation Reports Fourth Quarter and Fiscal Year 2011 Operating Results
8. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
9. American Pacific Reports Fiscal 2011 Results
10. Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
11. Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015  Par Pharmaceutical Companies, ... conference call on Friday, March 13, 2015 at ... operations for the fourth quarter and full year ... and currently makes certain financial information available to ... and Exchange Commission and will make certain other ...
(Date:3/6/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... milestone payment from Biogen Idec related to advancing the ... in infants with spinal muscular atrophy (SMA).  ... is a randomized, double-blind, sham-procedure controlled thirteen month ... study will evaluate the efficacy and safety of a ...
(Date:3/5/2015)... March 5, 2015 WuXi PharmaTech (Cayman) Inc. ... capability and technology platform company serving the pharmaceutical, biotechnology, ... the United States, today announced its financial results for ... Fourth-Quarter 2014 Highlights , Net Revenues Increased ... Laboratory Services Net Revenues Grew 17.7% Year Over Year ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 2Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 3Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 4Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22
... presented at the 2008 iSBTc Annual Meeting -, ... a.m. ET to discuss,results -, BRANFORD, Conn., Nov. ... preliminary data from an ongoing Phase II,trial of CR011-vcMMAE, ... patients with unresectable Stage III or Stage IV melanoma.,Dr. ...
... Clinical Study of Paliperidone ER in this Under-Studied ... with schizoaffective,disorder receiving paliperidone extended release tablets (paliperidone ... their symptoms, according,to a new study presented today ... San Diego, Calif.(1) In addition, safety findings were ...
Cached Medicine Technology:CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6
(Date:3/6/2015)... York, NY (PRWEB) March 06, 2015 ... of “Women’s Health,” a campaign that seeks to educate, ... role when it comes to their health and their ... the rise, it has never been more pertinent to ... rights. , The print component of “Women’s Health” ...
(Date:3/6/2015)... March 06, 2015 “ Pokemini ” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review and shared ... , Over the last couple of years, mobile games ... the game. For example, Candy Crush allows users to connect ...
(Date:3/6/2015)... Ticket Down is a reputable source for ... the Moda Center. After being away from the touring ... no signs of letting up on his “Garth Brooks World ... wife, Trisha Yearwood, to venues around the United States. The ... acclaimed tour to the Moda Center in Portland, OR. The ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues ... organization has hired two new Scientific Program Officers, Amanda ... report to Grace Pavlath, Ph.D, who joined MDA late ... Director, and together will lead MDA as it accelerates ... for various types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 US Sports ... three Maryland camps – two non-contact specialty camps and ... run by Perfect Performance Training, located at Bowie State ... on developing position specific skills, speed and strength of ... at Salisbury University with Marvin Graves, former quarterback in ...
Breaking Medicine News(10 mins):Health News:The Well-Woman: Encouraging Regular Screenings and Advocating for Women’s Health Rights with Mediaplanet’s “Women’s Health” Campaign 2Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2
... of genetics, environment caused mice to develop disease, study finds ... with mice, scientists have found a bacteria living in the ... rheumatoid arthritis. , The gut of all mammals is populated ... are essential for developing a normal immune system. But some ...
... Announcing a new Web ... to improve the look and strength of your abdominal muscles and improve overall health. Get ... site. , ... A new Web site has been developed to help anyone get in shape. If you ...
... ... to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA in Bayside, ... ... is pleased to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA ...
... ... Guidance Based on Experience at Pfizer, Merck, Medtronic, GTx, Johnson & Johnson, and the University ... ... 2010 -- To support its focus on regulatory compliance in the life sciences, openQ has ...
... now new areas in which whole body magnetic resonance imaging ... Deutsches rzteblatt International ( Dtsch Arztebl Int 2010; ... of possible uses, together with the limits of this radiation-free ... routine use in hospitals, as the procedure takes less than ...
... is an uncommon benign neoplasm with locally aggressive behavior but ... a 14-year-old patient with clinical presentations of abdominal pain and ... research article to be published on June 7, 2010 in ... A research team led by Professor Ko from Chang Gung ...
Cached Medicine News:Health News: Stomach Bacteria Might Trigger Rheumatoid Arthritis 2Health News: Stomach Bacteria Might Trigger Rheumatoid Arthritis 3Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 3Health News:openQ Announces the Formation of a Compliance Advisory Board 2Health News:openQ Announces the Formation of a Compliance Advisory Board 3
Poly stat Strep A is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid in the diagn...
... The CoaguChek S System offers ... in just one minute requiring only ... enable you to provide more comprehensive ... with each patient. The CoaguChek S ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: